Cytokinetics INC Form 4 insider transactions

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, sold 4,002 shares of common stock at a price of $36.68 on May 5, 2025.

Cytokinetics CEO Robert Blum sold 5,000 shares of common stock at a price of $40.96 on April 29, 2025, according to a Form 4 filing.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the exercise of stock options and subsequent sale of shares on April 22, 2025.

Wendall Wierenga, a director at Cytokinetics Inc, exercised stock options and sold shares on April 21, 2025, according to a recent SEC filing.

Director John T. Henderson exercised stock options and sold a portion of the acquired shares of Cytokinetics Inc. on April 15, 2025.

Director John T. Henderson acquired 551 shares of Cytokinetics Inc. common stock at $38.56 per share in lieu of a cash retainer.

Director Robert Arthur Harrington acquired 324 shares of Cytokinetics Inc. common stock at $38.56 per share through the Director Stock in lieu of Cash Retainer Plan.

Edward M. Kaye, a director at Cytokinetics Inc, acquired 324 shares of common stock through the Director Stock in lieu of Cash Retainer Program on April 15, 2025.

Director Wendell Wierenga acquired 162 shares of Cytokinetics Inc. common stock on April 15, 2025, through the Director Stock in lieu of Cash Retainer Program.

Director Nancy Wysenski acquired 162 shares of Cytokinetics Inc. common stock through the Director Stock in lieu of Cash Retainer Program.

Cytokinetics' President and CEO, Robert I. Blum, sold 5,000 shares of common stock at a price of $36.77 on April 10, 2025.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the exercise of stock options and subsequent sale of common stock on April 8, 2025.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 2,886 shares of common stock at a price of $35.78 on April 7, 2025.

Director Robert Arthur Harrington sold 450 shares of Cytokinetics Inc. common stock at a price of $39.43 on April 3, 2025.

Cytokinetics CEO Robert Blum sold 15,000 shares of common stock at $40.75 on March 31, 2025, according to a Form 4 filing.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports a gift of 200 shares of common stock.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold a portion of the acquired shares on March 18, 2025.

Sung Lee, EVP and CFO of Cytokinetics, reports the acquisition of common stock and stock options, along with the disposal of common stock, as per a recent SEC Form 4 filing.

EVP, Chief Commercial Officer of Cytokinetics, Andrew Callos, reports acquisition and disposal of common stock and derivative securities.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports acquisition of restricted stock units and stock options, as well as disposal of common stock.

Robert Blum, President & CEO of Cytokinetics, reports acquisition of restricted stock units and stock options, along with disposition of common stock.

EVP and Chief Commercial Officer of Cytokinetics, Andrew Callos, sold 2,775 shares of common stock on March 17, 2025, to cover the vesting of restricted stock units.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc, sold 4,389 shares of common stock on March 17, 2025, to cover taxes associated with the vesting of restricted stock units.

Cytokinetics CEO Robert Blum sold shares of common stock on March 17, 2025, to cover taxes associated with the vesting of restricted stock units.

Cytokinetics' President and CEO, Robert I. Blum, sold 25,000 shares of common stock at a price of $44.65 on March 17, 2025.

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, exercised stock options and sold shares on March 17, 2025.

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, exercised stock options and sold a portion of the acquired shares on March 14, 2025.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 26,771 shares of common stock on March 13, 2025, at a price of $43.62 per share.

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 3,341 shares of common stock on March 6, 2025, to cover a transaction related to the vesting of restricted stock units.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc, sold 8,228 shares of common stock on March 6, 2025, to cover a transaction related to the vesting of restricted stock units.